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RESUMO 
Introdução: As fraturas de fragilidade óssea são uma causa importante de 
morbimortalidade em todo o mundo. Embora mais frequentes nas mulheres, nos 
homens as fraturas da anca associam-se a pior prognóstico. No entanto, a fragilidade 
óssea masculina continua a ser um tema bastante negligenciado. Embora a 
determinação da densidade mineral óssea (DMO) seja um passo chave na avaliação da 
fragilidade óssea, o rastreio universal não é eficiente pelo que, alternativamente, se deva 
testar apenas indivíduos com maior probabilidade de ter baixa DMO. Diversas 
ferramentas de decisão clínica foram desenvolvidas com o objetivo de identificar esses 
indivíduos mas a sua validação em diferentes populações levou a grande 
heterogeneidade nos limites propostos para positividade, tornando a sua aplicabilidade 
confusa e alertando para necessidade da calibração das mesmas. Por fim, a maioria 
destas ferramentas é baseada em cálculos complexos pelo que, desde que assegurada 
validade semelhante, quanto mais simples for a ferramenta, mais provável será a sua 
adoção na prática clínica.  
Objetivos: Estudar a capacidade das ferramentas de decisão clínica identificarem 
homens com baixa DMO que beneficiem da realização de densitometria óssea, através 
de dois objetivos específicos: 1) descrever e comparar a validade das ferramentas de 
decisão clínica publicadas para identificar homens com baixa DMO através da 
elaboração de uma revisão sistemática; 2) calibrar as ferramentas OST e MORES para 
a nossa população e avaliar a sua capacidade discriminatória em relação a uma nova 
ferramenta clínica (EPIPOST), desenvolvida e validada no presente estudo, para 
identificar homens com baixa DMO. 
Objetivo 1: Na elaboração da revisão sistemática foram identificados, em base de 
dados eletrónica (Medline) e na lista de referências dos artigos incluídos, estudos que 
descrevessem a validade de instrumentos de predição de baixa DMO em homens. Após 
uma primeira seleção por leitura dos títulos e resumos de todas as citações, foi feita 
uma segunda seleção por leitura completa dos artigos selecionados. Foram colhidos 
dados de forma estruturada a partir dos artigos selecionados relativamente a 
características dos participantes, especificidades da densitometria óssea e 
propriedades da ferramenta validada em termos de fatores de risco incluídos e medidas 
de capacidade discriminativa calculadas. A qualidade metodológica foi avaliada através 
de uma versão modificada da lista QUADAS.  
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Foram identificadas 1484 citações: 1447 foram excluídas após leitura do título e resumo 
uma vez que não cumpriam os critérios de inclusão. Os restantes 37 artigos foram lidos 
integralmente. No final, foram incluídos 22 artigos: 2 estudos avaliaram a capacidade de 
5 guidelines para realização de densitometria óssea propostas por diferentes entidades; 
5 estudos desenvolveram e validaram 5 novas ferramentas de rastreio mas destas 
apenas 2 foram posteriormente validadas noutras populações; 12 estudos avaliaram a 
capacidade do OST, 4 a do MORES e 3 a do OSTA. Verificou-se grande 
heterogeneidade entre os estudos [em termos de características da amostra (população 
de base, idade, raça); medição da massa óssea (equipamento de densitometria e 
avaliação da qualidade), diagnóstico de baixa DMO (população de referência para o 
cálculo do T-score, local anatómico selecionado)] e a qualidade global foi moderada tal 
como evidenciado por uma média de 10.8 itens, com variação entre 8 e 15, em 19 
possíveis na lista QUADAS modificada. Embora nenhuma das ferramentas se tenha 
mostrado consistentemente melhor que a outra nem houvesse consenso relativamente 
ao melhor valor limite para positividade, todas mostram capacidade preditiva razoável 
pelo que se deve optar pela de mais simples execução. 
Objetivo 2: Como parte do estudo de base populacional em adultos EPIPorto foram 
avaliados 147 homens entre os 40 e os 65 anos. Foram registados idade, altura, peso, 
índice de massa corporal e diversas circunferências corporais. Para avaliação da DMO 
foi realizada densitometria de corpo inteiro. Para a calibração das ferramentas OST e 
MORES, foram estimados novos parâmetros de regressão baseados nas caraterísticas 
da nossa população. No desenvolvimento da nova ferramenta de rastreio EPIPOST, as 
diferentes medidas antropométricas para prever baixa DMO foram testadas através de 
diferentes modelos de regressão logística. A validação do EPIPOST foi realizada pelo 
método leave-one-out cross-validation. O ajuste global e capacidade discriminatória 
foram testados por comparação direta dos valores previstos e estimados de baixa DMO 
por quartil de pontuação de cada ferramenta, pelo teste de “goodness-of-fit” Hosmer-
Lemeshow e pela área sob a receiver operating characteristic curve (AUC). Finalmente, 
foram calculados likelihood ratios (LR) para selecionar os limites de positividade mais 
adequados para cada ferramenta.  
A calibração manteve a capacidade discriminatória do OST e do MORES (AUC 0.73 e 
0.75, respetivamente) e melhorou o ajuste dos modelos à nossa população. O 
EPIPOST, que incluiu apenas a circunferência do braço relaxado, mostrou ligeiramente 
melhor capacidade discriminatória (AUC 0.76) que as outras ferramentas. A análise de 
LR mostrou que o EPIPOST apresenta maior capacidade discriminativa ao longo dos 
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diferentes níveis de risco (LR a variar entre 0.1 e 18.4, em comparação com 0.0 e 2.4 
com o OST e 0.2 e 2.8 com o MORES). 
Para prever baixa DMO, um OST≤2 teve sensibilidade de 100% e especificidade de 
8.2%; um MORES>-2 teve sensibilidade de 93.9% e especificidade de 30.6%; um 
EPIPOST>-2 teve sensibilidade de 98.0% e especificidade de 18.6%. A validação do 
EPIPOST revelou que a concordância entre os valores observados e previstos foi 
aceitável (73.3% na amostra de desenvolvimento e 71.2% nas amostras de validação). 
Conclusões: A nossa revisão sistemática identificou 22 estudos que validavam 9 
ferramentas. No entanto, destas, apenas 3 (OST, OSTA e MORES) foram validadas 
mais que uma vez em populações masculinas. Foi constatada elevada heterogeneidade 
metodológica entre os estudos identificados e não houve concordância quanto ao limite 
para positividade mais adequado para cada ferramenta. Ainda assim, todas as 
ferramentas mostraram razoável capacidade preditiva e nenhuma foi superior às 
demais, pelo que o OST e o MORES, dada a sua simplicidade, capacidade preditiva e 
replicação, parecem ser mais adequados para uso na prática clínica. A calibração das 
ferramentas OST e MORES melhorou o ajuste de ambos os modelos à nossa população 
embora a capacidade discriminatória para identificar homens com baixa DMO se tenha 
mantido. A ferramenta desenvolvida por nós especificamente para homens, o EPIPOST, 
mostrou ter melhor capacidade discriminativa que o OST e que o MORES, bem como 
ser mais fácil de executar. A análise de likelihood ratios mostrou que indivíduos que 
pontuassem OST≤2, MORES> -2 ou EPIPOST>-2 tinham maior probabilidade de ter 
baixa DMO e, portanto, deviam realizar densitometria óssea.  
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ABSTRACT 
Introduction: Bone fragility and associated fractures are an important cause of morbidity 
and mortality worldwide. Even though lifetime risk of hip fracture is higher in women, 
fragility fractures are associated with worst prognosis in men. Nevertheless, male 
osteoporosis remains a neglected condition. Although bone mineral density (BMD) 
determination is a key step for bone fragility assessment, mass screening is not cost-
effective. An alternative involves testing only individuals with higher probability of low 
BMD. Several clinical decision rules have been developed with this objective but their 
validation across different populations has led to heterogeneity in the proposed cut-offs, 
making its applicability unclear and calling for calibration. Finally, most of these tools are 
based on complex calculations. However, when similar validity can be ensured, the 
simpler the clinical screening tool the more likely it is to be applied in clinical practice. 
Aims: To study the capacity of clinical decision rules to identify men with low BMD who 
should undergo dual-energy x-ray absorptiometry (DXA) testing through the following 
specific objectives: 1) to describe and compare the validity of published clinical screening 
tools designed to identify men with low bone mineral density trough the elaboration of a 
systematic review; 2) to calibrate OST and MORES tools to our population and to assess 
their discriminatory ability against a newly developed and validated simplified clinical 
screening test (EPIPOST) to identify men with low BMD. 
Objective 1: For the systematic review elaboration, we identified studies describing the 
validation of instruments for low bone mass prediction in men in electronic database 
(Medline) and reference lists of included articles. After screening all titles and abstracts, 
the selected articles were rescreened by full text reading. Data were extracted on 
participants’ characteristics, DXA features and tools’ properties in terms of risk factors 
included and discriminatory performance of all selected studies. Methodological quality 
was assessed using a modified QUADAS checklist.  
A total of 1484 citations were identified with our search: 1447 were excluded after 
screening the title and abstract as they did not met our inclusion criteria. The remaining 
37 articles were submitted to full-text reading. At the end, 22 articles were included in 
our systematic review: 2 studies assessed the performance of 5 guidelines for DXA 
testing proposed from different entities; 5 studies developed and validated 5 new 
screening tools but of these only 2 were further validated in other populations; 12 studies  
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evaluated the performance of OST, 4 assessed the performance of MORES and 3 
estimated the performance of OSTA. There was high heterogeneity across studies [in 
terms of sample characteristics (source population, age, race); bone mass assessment 
(DXA equipment and quality assessment), low bone mass diagnosis (reference 
population for T-score calculation, anatomical site selected)] and the global quality was 
moderate as showed by a mean of 10.8 items, with a range of 8-15, in 19 possible 
modified QUADAS items. Despite substantial variability regarding the most accurate cut-
off, all tools showed moderate predictive capacity and any performed consistently better 
than other, denoting that the simplest to execute should be preferred.   
Objective 2: As part of EPIPorto population-based study among adults, 147 men aged 
between 40 and 65 years were assessed. Age, height, weight, body mass index and 
several body circumferences were recorded. DXA whole-body scans were performed for 
BMD assessment. For OST and MORES calibration, new regression parameters were 
estimated based on our population features. For EPIPOST development, the different 
anthropometric variables were tested using logistic regression models to predict low 
BMD. EPIPOST validation was done by the leave-one-out cross-validation method. The 
overall fit and discriminatory capacity were assessed by direct comparison of the 
observed and expected prevalences of low BMD by quartiles of each score, Hosmer-
Lemeshow “goodness-of-fit” test and area under the receiver operating characteristic 
curve (AUC). Finally, likelihood ratios (LR) were calculated to select the ideal cut-off for 
each model. 
Calibration maintained the discriminatory capacity of OST and MORES (AUC 0.73 and 
0.75 respectively) but improved the fitting. EPIPOST included only relaxed upper arm 
circumference and showed slightly better discriminatory capacity (AUC 0.76) than the 
other tools. The LR analysis showed that EPIPOST had higher discriminative ability 
across different risk levels (LR range of 0.1 to 18.4, compared to 0.0 to 2.4 with OST and 
0.2 to 2.8 with MORES).  For predicting low BMD, OST≤2 had a sensitivity of 100% and 
a specificity of 8.2%; MORES>-2 had a sensitivity of 93.9% and a specificity of 30.6%; 
EPIPOST>-2 had a sensitivity of 98.0% and a specificity of 18.6%. EPIPOST leave-one-
out cross-validation showed that the agreement between the observed and predicted 
values was acceptable (73.3% in the training sample and 71.2% across validation 
samples). 
Conclusions: Our systematic review identified 22 studies validating 9 tools aimed to 
identify men with low BMD more likely to benefit from DXA testing. However, of these, 
only 3 (OST, OSTA and MORES) were validated in more than one sample. Despite high 
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methodological heterogeneity across studies and uncertainty regarding the most 
accurate cut-off, all tools showed reasonable predictive capacity and any performed 
better than the others. OST and MORES, for their simplicity, accuracy and replication, 
seem to be more adequate for routine clinical practice use. Calibration of OST and 
MORES improved the fitting of both models to our population data while maintaining their 
discriminatory ability to identify men with low BMD. The newly developed tool specifically 
for men, EPIPOST, proved to have even better discriminatory ability than OST and 
MORES despite being simpler to execute. The likelihood ratios analysis revealed that 
individuals scoring OST≤2, MORES>-2 and EPIPOST>-2 should undergo DXA testing.  
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INTRODUCTION 
 
Condition 
Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and 
microarchitectural deterioration of bone tissue that increases bone fragility and risk of 
fractures [1]. Low-energy fractures, also known as fragility fractures, are the main 
complication of the condition. A fragility fracture results from forces that would not 
normally cause a fracture, such as a hip or wrist trauma from falling from standing height 
or low-energy vertebral compression. Although specific fracture sites have been 
considered more characteristic of osteoporosis, fractures occurring at nearly every 
anatomical site have been associated with bone fragility [2]. 
 
Prevalence and Burden of Osteoporosis 
Osteoporosis and osteoporotic fractures are rare before the age of fifty years. However, 
their prevalence rises with age thereafter and it was estimated that in Europe 
approximately 6% of all men and 21% of all women aged 50–84 years have osteoporosis 
[3]. It has been also estimated that, between 2010 and 2050, the prevalence of 
osteoporosis will increase by 40% in women and 81% in men and fragility fractures will 
raise by 218% in women and 335% in men [4].  
More importantly, the incidence of non-vertebral fractures has been estimated of 9.6 
(95% CI, 8.3 - 11.0) per 1000 person-years in men and 25.0 (95% CI, 23.3 - 26.9) per 
1000 person-years in women [5]. Information about vertebral fractures is more difficult to 
deliver as they are often subclinical and usually managed in ambulatory and, therefore, 
remain unidentifiable through hospital databases.  
Amongst patients who have experienced fractures, it is well documented that fewer than 
50% are ever assessed or treated for osteoporosis [6]. This has major significance as 
fragility fractures are associated with an increase in mortality [7]. It was estimated that 
approximately 34,000 deaths annually are caused by fractures in Europe [3].  
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However, in terms of disease burden, it is more important to consider the excess 
mortality due to fragility fractures. Excess mortality is substantial after hip fracture, 
depending on the time since the event (higher in the immediate fracture period untill the 
end of the first year) but also on age and sex of the individuals [8].  
 
Specific aspects of osteoporosis in men 
Even though the lifetime risk of hip fracture was estimated as 8.9% (95% CI, 2.3 - 15.4%) 
in women and 6.7% (95% CI, 1.2 - 12.2%) in men [9] it is known that fragility fractures 
denote worst prognosis in the male sex: the cumulative mortality at 12 months among 
individuals with hip fracture patients compared to the general population was 37.1% in 
men and 26.4% in women [10]. The reasons relate to the higher general population 
mortality in men but also with the higher relative risk of death after fracture in men 
compared with women [3]. 
Nevertheless, male osteoporosis remains a neglected condition: Papaioannou et al. [11] 
reported a diagnostic and therapeutic care gap in a sample of men with fragility fractures 
whit only 2.4% of these reporting an osteoporosis diagnosis. For many years, 
osteoporosis has been considered to be a condition associated with postmenopausal 
women. This misconception has led to underreferral of men for dual-energy X-ray 
absorptiometry (DXA) and, consequently, underdiagnosis of osteoporosis even in the 
presence of fragility fractures.  
In terms of clinical research, there is also a paucity of reported clinical studies exploring 
the low bone mineral density (BMD) in men, for example, in terms of reports studying the 
efficacy of osteoporosis therapy, when compared with large studies conducted in women 
[12]. 
 
Diagnosis  
Osteoporosis is diagnosed in individuals on the basis of presence of a fragility fracture 
or by bone mass measurement criteria [2].  
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The definition of an osteoporotic fracture is not straightforward and there are diverging 
opinions on what to consider an osteoporotic fracture. One approach is to consider those 
resulting from low energy trauma, defined as a fall from a standing height or less, or 
trauma that in a healthy individual would not give rise to fracture [13].  Data from a 
systematic review state that the fractures most likely related to osteoporosis were those 
at the femoral neck and lumbar and thoracic vertebrae. The fractures rated least likely 
because of osteoporosis were open proximal humerus fractures, skull, and facial bones 
[14]. 
The goal in osteoporosis management is to avoid fracture. Therefore clinicians must 
seek upstream for asymptomatic patients and assess characteristics that pertain to bone 
physical properties. The description of osteoporosis captures the notion that low bone 
mass is an important component of the risk of fracture, but other abnormalities occur in 
the skeleton that contribute to skeletal fragility. Indeed, bone strength is determined by 
bone mineral density, cortical thickness and porosity, trabecular bone morphology, and 
intrinsic properties of bony tissue [15]. Ideally, the assessment of the skeleton should 
capture all these aspects. However, bone mass and area (and their composite measure 
bone mineral density) remain the parameters routinely measured in clinical practice 
despite capturing only a part of overall bone strength. Nevertheless, it has been 
estimated that BMD measured by DXA accounts for 60-70% of bone strength variability 
in the population [15].  
Bone mineral density criteria for the definition of osteoporosis were proposed by the 
World Health Organization (WHO) from epidemiologic data that describe the normal 
distribution of BMD in a young healthy reference population [16]. BMD is the amount of 
bone mass per unit volume (volumetric density, g/cm3), or per unit area (areal density, 
g/cm2), and both can be measured in vivo. A large variety of techniques is available but 
the most widely used techniques by far are based on X-ray absorptiometry in bone, 
particularly DXA that measures areal BMD. The distribution of bone mineral content or 
density in young healthy adults (representing “peak bone mass”) is approximately 
normal, irrespective of the measurement technique used. Because of this normal 
distribution, bone density values in individuals may be expressed in relation to a 
reference population in standard-deviation (SD) units. When SDs are calculated in 
relation to the mean of a young healthy population, this is referred to as the T-score [3]. 
It has been estimated that for each SD decrease in BMD, measured by DXA, the risk of 
hip fracture increases 2.6-fold [17]. This risk gradient led, in 1994, to the publishing of 
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the WHO osteoporosis diagnostic criteria based on the T-score measured at the hip, 
spine or forearm, with T-score≥-1.0 being considered normal, -2.5<T-score<-1.0 
considered osteopenia and T-score≤-2.5 considered osteoporosis [16]. More recently, 
the femoral neck has been adopted as the standard measurement site and the reference 
population for both men and women T-score calculation being the mean and SD values 
in young women from the NHANES III study [18]. 
 
Screening for osteoporosis 
Even though BMD measurement by DXA is considered the gold standard assessment 
for determining who has low BMD, screening the entire population of men with DXA 
scans has very low efficiency due to low pre-test probability, suboptimal DXA availability 
and elevated costs. 
A worthwhile alternative involves identifying men with higher probability of low BMD who 
will subsequently be suitable candidates for DXA screening, as determined through 
screening tools composed by risk factors for low BMD. These screening tools increase 
DXA screening efficiency and cost-effectiveness by reducing the number of men referred 
who are otherwise healthy. 
Ideally, a screening test should be 100% sensitive and 100% specific. However, in 
practice, this does not occur as sensitivity and specificity are usually inversely related. A 
test with good sensitivity is favoured when a false-negative result is more prejudicial for 
the patient than a false-positive one (curable disease, early diagnosis associated with 
better prognosis) or when the disease is uncommon. A test with a good specificity is 
favoured when a false-positive result is more prejudicial for the patient than a false-
negative one (aggressive treatment, incurable disease, condition with heavy labelling 
effect, etc.) [19].  
In case of a false-positive result from an osteoporosis screening tool, there is no risk of 
harm to the patient from unnecessary treatment or invasive diagnostic testing because 
treatment for low BMD would only be initiated upon confirmation by DXA, a safe and 
non-invasive diagnostic procedure. In this way, more importance has to be given to 
sensitivity rather than specificity when developing a clinical decision rule in this field. In 
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terms of likelihood ratios, this means that screening tests should be associated to low 
negative likelihood ratios. 
 
Screening in men 
Several screening strategies have been proposed to identify men who benefit the most 
from DXA testing. Worldwide, different guidelines have been written for the diagnostic 
evaluation of male osteoporosis but they are not as well validated as in postmenopausal 
osteoporosis.  
The 2010 NOF (National Osteoporosis Foundation) Clinician’s Guide recommends DXA 
testing in men with specific conditions (e.g., rheumatoid arthritis) or on specific 
medications (e.g., glucocorticoids in a daily dose ≥5 mg prednisone or equivalent for ≥3 
months) that may predispose to bone loss, in men age 70 and older regardless of clinical 
risk factors as well as in men aged 50-70 when they have a prior fragility fracture or 
because of clinical risk factors [20]. The Portuguese Society of Rheumatology also 
recommends that all men above 70 years should undergo DXA testing and that the 
remaining should only be tested depending on the presence of other risk factors for low 
BMD [21]. However, the accuracy of the criteria proposed in these recommendations for 
selecting patients to DXA has not been estimated and these guidelines also lack cost-
effectiveness assessment. In fact, despite widespread screening of men older than 70 
years has been claimed, Schousboe et al. [22] reported that universal screening would 
probably be cost-effective only in men aged 80 years or older. 
These facts highlight the necessity of a tailored approach in screening for low BMD in 
men. Instead of empirical guidelines based on risk factors associated with low BMD, it 
has been proposed that clinicians should follow clinical decision rules that have been 
validated, an option which may require several studies to fully test the accuracy of the 
rule in different clinical settings [23]. 
In the last twenty years, several clinical decision rules have been developed with the 
objective of identifying individuals with low BMD who should undergo DXA testing. They 
comprise various components of the medical history, physical examination, laboratory 
results and other complementary exams (e.g., ultrasound). As a whole, clinical decision 
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rules inform clinical judgment and have the potential to change clinical behaviour and 
reduce unnecessary costs while maintaining quality of care. [23]. 
 
Clinical screening tools 
Specifically, decision rules based only on variables from the medical history and physical 
examination (clinical screening tools) have many advantages as they provide more 
readiness in the information availability and avoid costs, time consumption and adverse 
events (for example in the case of ionizing radiation) related to additional complementary 
exams. 
The implementation of clinical screening tools is being attempted in many medical areas, 
mainly because they represent a way to improve the quality of care while reducing health 
costs. 
Although there are few studies of the cost-effectiveness of clinical screening tools in 
osteoporosis, Shepherd et al. [24] estimated that the clinical utility of Male Osteoporosis 
Risk Estimation Score (MORES), as measured by the number needed to screen (NNS) 
to prevent 1 additional hip fracture, compared favourably with the United States 
Preventive Services Task Force (USPSTF) findings for women: USPSTF recommended 
universal DXA testing for women aged 65 years with a NNS of 731 to prevent 1 additional 
hip fracture; MORES, with similar assumptions of subsequent treatment, adherence, and 
fracture reduction in those diagnosed with osteoporosis, resulted in a NNS to prevent 1 
additional hip fracture of 544 in men aged 60 to 64 years.  
Since the mid-1990s several articles appeared in the literature regarding pre-screening 
instruments to select patients for DXA testing. Each of these instruments focused on 
different characteristics, sometimes with overlap, to reach different decision points with 
different cut offs. Specifically in men, a meta-analysis from 2008 [25] found 5 articles 
concerning clinical screening tools to identify men with low BMD. Since then, new tools 
were developed and a number of papers to assess the accuracy of previously developed 
clinical screening tools in different populations has been published.  
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The validation of these screening tools across different populations has led to 
heterogeneity in values selected as screening thresholds at which DXA is recommended 
[25], making its applicability in clinical practice confusing. This fact calls for the need to 
calibrate these tools for specific populations rather than only constantly change the 
decision thresholds.  
Finally, most of the developed screening tools are based on complex calculations using 
self-reported variables such as age and weight. However, self-reported weight is known 
as a subject of important information bias when compared to measured weight, 
particularly in men [26]. Therefore, when similar validity can be ensured, the simpler the 
clinical decision rule the more likely it is to be applied in real clinical settings. 
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AIMS 
 
The aim of this thesis was to study the capacity of clinical decision rules to identify men 
with low BMD who should undergo DXA testing through the following specific objectives: 
1. To describe and compare the validity of published clinical screening tools 
designed to identify men with low bone mineral density trough the elaboration 
of a systematic review. 
2. To calibrate OST and MORES tools to our population and assess their 
discriminatory ability against a newly developed and validated simplified 
clinical screening test (EPIPOST) to identify men with low BMD. 
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CHAPTER I 
 
Clinical screening tools to identify men with low bone mass: a 
systematic review 
Romana Vieira, Fábio Araújo, Carla Lopes, Raquel Lucas 
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Abstract 
Objective: To identify and assess the accuracy of published clinical screening tools 
designed to identify men with low bone mineral density (BMD). Methods: We identified 
studies describing the validation of instruments for low bone mass prediction in men 
through an electronic database search (Medline), including reference lists of eligible 
articles. We screened for inclusion first by reading the title and abstract of all retrieved 
references and then by full text reading of the articles selected in the first phase. Data 
were extracted on participants’ characteristics, dual-energy x-ray absorptiometry (DXA) 
features and tools properties in terms of risk factors included and discriminatory 
performance. Methodological quality was assessed using a modified QUADAS checklist. 
Results: A total of 1484 citations were identified with our search strategy: 1447 were 
excluded after screening the title and abstract as they did not met our inclusion criteria. 
The remaining 37 articles were submitted to full-text reading. At the end, 22 articles, were 
included in our systematic review: 2 studies assessed the performance of 5 guidelines 
for DXA testing proposed by different entities; 5 studies developed and validated 5 new 
screening tools but of these only 2 were further validated in other populations; 12 studies 
evaluated the performance of OST, 4 assessed the performance of MORES and 3 
estimated the performance of OSTA. There was high heterogeneity across studies 
(regarding source populations, age distribution, ethnic background, low BMD diagnostic 
criteria, DXA equipment) and the global quality of the reports was moderate as shown 
by a mean of 10.8 items, with a range of 8-15, in 19 possible modified QUADAS items. 
No tool performed consistently better than the others and none of the cut-offs tested was 
evidently more accurate than the alternatives for each score. Conclusion: Nine 
instruments were validated in 22 studies. However, only 3 (OST, OSTA and MORES) 
had been validated in more than in one sample. Overall, even though no clear cut-offs 
for any of the scores emerged from our analysis, all tools had acceptable predictive 
capacity and performed similarly in terms of overall accuracy. OST and MORES, for their 
simplicity, accuracy and replication, seem to be more adequate for routine clinical 
practice use. 
Keywords: Men, Bone Density, Screening, Clinical Prediction Rule, Systematic Review. 
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Introduction 
Osteoporosis is a disease defined by decreased bone mass and alteration of bone micro 
architecture which results in increased bone fragility [1] with a growing incidence 
worldwide. Although it mostly affects postmenopausal women, it is known that fracture, 
its major consequence, has worse prognosis in men regarding not only morbidity but 
also mortality [2]. 
Since bone mass assessment using dual-energy X-ray absorptiometry (DXA) is the gold 
standard method to diagnose osteoporosis [3], several clinical decision rules (CDR) have 
been developed to help clinicians deciding who should undergo DXA examination. A 
CDR quantifies the independent contribution of each component of the clinical history, 
physical examination and basic laboratory results towards a specific condition in an 
individual patient [4] with the objective of increasing the clinician´s diagnosis accuracy 
through a case-finding strategy. In the bone health field, since the mid-1990s, clinical 
screening tools have been developed to select patients for bone densitometry [5]. 
However, at present, there is no universally accepted policy for population screening in 
Europe to identify patients with osteoporosis or those at high risk of fracture. 
Most osteoporosis screening tools have been developed in women and some of those 
were subsequently validated in men. More recently, attending for gender heterogeneity 
in terms of candidate bone mineral density (BMD) predictors, some groups developed 
male-specific osteoporosis screening tools. However, none of them has found broad 
acceptance in medical practice so far and there is no wide consensus on their 
recommended cut-off values. The election of a specific tool in detriment of others would 
be enhanced if one proved to be more accurate in terms of predictive ability and/or easier 
to apply, such as composed solely of clinical risk factors. However, to the best of our 
knowledge, the only synthesis of published evidence on CDR in men dates from 2008, 
even though a number of new validation studies have been conducted and published 
since then [6].  
The objective of the present systematic review was to identify and assess the accuracy 
of published clinical screening tools designed to identify men with low bone mineral 
density.  
23 
 
Methods 
We followed the current analytical methods and standards established by the Preferred 
Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) group for 
systematic reviews and meta-analysis [7]. 
Eligibility criteria 
We included articles written in English, French, Spanish, Italian and Portuguese. 
 Population: adult male. 
 Intervention: validation of prognostic instruments to identify individuals with an 
increased risk of low bone mineral density - development of risk assessment tools 
was included if they were derived from an initial population and then validated 
internally or externally). Due to the practical value of the tool, we have considered 
scores including only clinical risk factors (not derived from complementary 
diagnostic exams). 
 Included studies had to report characteristics of the screening tool performance 
[(sensitivity, specificity or area under the receiver operating characteristic curve 
(AUC)]. 
 Outcome: bone mineral density measured by DXA at femoral neck, total hip or 
lumbar spine. 
We excluded case reports, non-systematic reviews, letters to the editor, editorials and 
commentaries. Screening tools developed in populations defined based on specific 
diagnosis were also excluded even though we accepted studies on screening tools 
developed in population based samples and subsequently validated in specific 
populations. 
Search 
The studies were identified by searching Medline (PubMed). The final electronic search 
was undertaken on August 27, 2013. Additionally, we hand-searched the reference list 
of all relevant studies (including two previous reviews). 
To generate search terms we conducted a preliminary search using known terms and 
synonyms suggested by clinicians and experts in the field to reach all possible words 
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related to our study objective. Additionally we added terms and keywords found in 
relevant studies to augment our search sensitivity. 
We used the following search strategy in MEDLINE (PubMed): (osteoporosis OR 
osteopenia OR bone mass) AND (instrument OR questionnaire OR models OR algorithm 
OR scores OR tool) AND ((((((((validity OR validation OR "sensitivity and specificity"[All 
Fields]) OR "specificity"[All Fields]) OR "screening"[All Fields]) OR "false positive"[All 
Fields]) OR "false negative"[All Fields]) OR "accuracy"[All Fields])) OR (((("predictive 
value"[All Fields] OR "predictive value of tests"[All Fields]) OR "predictive values"[All 
Fields])) OR ("reference value"[All Fields] OR "reference values"[All Fields]) OR 
((((("roc"[All Fields] OR "area under curve" [All Fields]) OR "roc auc"[All Fields]) OR "roc 
curve"[All Fields]) OR "roc curves"[All Fields]) OR "likelihood ratio"[All Fields])))) NOT 
(animals NOT humans) AND (male or men). 
Study selection 
The first eligibility assessment was conducted by one researcher and consisted in 
screening the title and abstract of all identified records. Subsequently, two researchers 
including the one who initially screened the references performed a full text read of 
potentially relevant studies. At this point disagreements between reviewers were 
resolved by consensus. 
Data collection process 
For data collection we developed and applied an extraction sheet to the final list of 
selected articles for inclusion in the systematic review. This extraction sheet was based 
on others mentioned in earlier systematic reviews on osteoporosis screening tools in 
women [8]. On each study we extracted data on: participant’s characteristics (number, 
age, geographical location and clinical context); screening tool features (variables 
included, development strategy, statistical methods); outcome assessment (DXA 
equipment and method and site of BMD measurement). In case of studies developing 
new screening that tools present data from development and validation samples, we 
extracted only data from the validation sample. 
For every study, sensitivity, specificity and AUC were extracted as the principal 
measures of the performance of screening tools. Positive and negative likelihood ratios 
(LR) were calculated for each proposed cut-off.  
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Risk of bias in individual studies 
For assessing risk of bias we used a modified version of the Quality Assessment Tool 
for Diagnostic Accuracy Studies (QUADAS) [9] checklist as proposed in previous studies 
[10]. 
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Results 
Study selection 
A total of 1484 citations were identified with our electronic search. The hand search of 
reference lists did not retrieve any new paper. Of the initial 1484 studies, 1447 were 
excluded after screening the title and abstract as they did not met our inclusion criteria. 
The remaining 37 articles were submitted to full-text reading. At the end, 22 articles were 
included in our systematic review. The study selection process, as well as reasons for 
exclusion, are summarized in Figure 1. 
Studies characteristics 
We report performance information of seven tools tested in 22 studies. Each study may 
have tested more than one osteoporosis screening tool. 
As more than one study presented performance data for more than one threshold for low 
BMD, we present the data from the 22 selected articles in 3 independent tables according 
to low BMD cut-off: Table 1 presents characteristics of studies on the performance of 
clinical screening tools to identify men with T-scores≤-2.5; Table 2 refers to T-scores≤-
2.0 and Table 3 refers to T-scores≤-1.0. 
The sample size ranged from 64 to 6572 individuals and relatively to the source 
population, only 9 studies were considered population based. The remaining referred to 
individual from general outpatient clinics (4 studies) or patients from specialty clinics (7 
studies). One study did not report source population. Finally, one study assessed the 
accuracy of the Osteoporosis Screening Tool (OST) in patients with rheumatoid arthritis.  
In terms of mean age there was also a wide range of values, from 47.0 to 73.0 years. 
The most commonly included risk factors in the final tool were age and weight even 
though other variables as chronic obstructive pulmonary disease, emphysema, 
gastrectomy, inactivity, personal or family history of fractures and weekly calcium intake 
were also mentioned. 
Most studies reported the DXA equipment utilized but only 17 gave additional information 
about the specific model. As to the site elected for osteoporosis definition, many studies  
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reported more than one site. The most prevalent definition was based on either hip or 
the lumbar spine (14 studies), followed by the hip (10 studies) and finally the lumbar 
spine (6 studies). One study did not report information about this item. In terms of 
reference group for the T-score calculation, at the femoral neck, only one study selected 
the young white women from the National Health and Nutrition Examination Survey 
(NHANES) population. The remaining selected either young men from NHANES 
population, the manufacturer’s built-in population data or country-specific populations. 
For the lumbar spine the most frequently used references were derived from young male 
populations selected by the manufacturer or specific from each country. 
Two studies evaluated the performance of previously established clinical practice 
guidelines to identify men with low BMD [11, 12] and five studies developed and validated 
5 new models specifically to identify men with low BMD [13-17]. However, of those, only 
the Osteoporosis Screening Tool for Asians (OSTA) [18, 19] and the Males Osteoporosis 
Risk Estimation Score (MORES) [20-22] were further validated in different populations. 
Logistic regression analysis was the method selected to derive the instrument in four of 
the five studies that developed new screening tools. However, one study choose to use 
linear regression analysis [13]. 
Two osteoporosis screening tools initially developed in women were validated in men: 
the Khon Kaen Osteoporosis Study (KKOS) [23] and, more extensively, OST [14, 19, 21, 
24-32]. 
Overall, there was high heterogeneity across studies in terms of sample characteristics 
(source population, age, race); bone mass assessment (DXA equipment and quality 
assessment), low bone mass diagnosis (reference population for T-score calculation, 
anatomical site selected). Due to this heterogeneity, we decided not to perform a 
quantitative synthesis of the results. Nevertheless, enough data were available to 
elaborate a qualitative comparison between different populations of the performance 
characteristics of OST [14, 19, 21, 24-32], MORES [15, 20-22] and OSTA [17-19] to 
predict a T-score≤-2.5 (OST, MORES and OSTA) and a T-score<-2.0 (OST). Tools 
whose validation was performed in a single population are listed in the tables but not 
included in the following comparative description, as data on performance reproducibility 
are warranted to decide on the field implementation of any clinical decision rule. 
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Performance of screening tools to identify men with T-score<-2.0 
When identifying men with T-score<-2.0 at the lumbar spine, femoral neck or total hip, 
OST estimated AUC ranged from 0.695 to 0.830. Different cut-offs were presented, from 
OST<-1 to OST<4, with sensitivity and specificity ranging from 62 to 83% and 57 to 89%, 
respectively. The lowest and highest positive LR were 1.93 and 5.64, respectively. The 
values for the negative LR ranged from 0.30 to 0.43. 
Performance of screening tools to identify men with T-score< -2.5 
For OSTA, at the femoral neck, the estimated AUC ranged from 0.848 to 0.850. With 
OSTA<-1 the estimated sensitivity and specificity ranged from 83 to 91% and 66 to 67%, 
respectively. At the lumbar spine, femoral neck or total hip, the estimated AUC was 
0.780. Different cut-offs were presented, from OSTA<-1 to OSTA<4, with sensitivity and 
specificity ranging from 38 to 77% and 43 to 82%, respectively. The estimated positive 
LR ranged from 1.27 to 2.68 and the negative LR from 0.14 to 0.76. 
Regarding MORES, at the femoral neck or total hip, the reported AUC estimated ranged 
from 0.820 to 0.842. A MORES≥6 had a sensitivity ranging from 80 to 95% and a 
specificity ranging from 61 to 70%. The lowest and highest positive LR were 1.29 and 
2.67, respectively. In terms of negative LR, the lowest value was 0.00 and the highest 
was 0.73. 
The performance of OST to predict a T-score<-2.5 at the lumbar spine, femoral neck or 
total hip, in terms of AUC, ranged from 0.667 to 0.890. The tested cut-offs varied 
extremely from OST<-3 to OST<8. At the different thresholds, sensitivity ranged from 7 
to 95% and specificity from 23 to 99%. When predicting T-score<-2.5 at lumbar spine, 
AUC ranged from 0.660 to 0.717, sensitivity ranged from 36 to 64% and specificity from 
60 to 80%. OST predicted T-score<-2.5 at femoral neck with estimated AUC ranging 
from 0.740 to 0.990. At the presented cut-offs, sensitivity varied from 6 to 100% and 
specificity from 51 to 94% with positive LR from 1.00 to 14.00 and negative LR from 0.00 
to 1.00. Interestingly, one study found that OST performed much better in African 
American than Whites (in Whites, the best discriminatory capacity corresponded to 
OST<4 with a positive and negative LR of 1.73 and 0.29, respectively; in African 
American, the best discriminatory capacity was found at OST<2, with a positive and 
negative LR of 5.88 and 0.00).  
29 
 
Finally, a study assessing the performance of OST in men with rheumatoid arthritis 
found, at the proposed cut-off of OST≤4, a sensitivity of 78% and a specificity of 45% for 
identifying osteoporosis; for identifying low BMD its sensitivity was 64% and specificity 
was 54%. 
Risk of bias within studies 
According to our assessment, the 22 included studies validating tools to predict low BMD 
fulfilled a mean of 10.8 items, with a range of 8-15, in 19 possible modified QUADAS 
items. Only 6 studies [15, 16, 19, 20, 25, 30] could be considered population based, 
meaning, including unselected men from the general population that would receive the 
test in a usual screening program. Most of the studies were relatively small (n=17) and 
it was unclear if the data regarding risk factors was collected blindly to DXA results and 
also if the DXA was interpreted blindly to the screening tool result. None of the selected 
studies reported information on uninterpretable test results. Further information on each 
QUADAS item is presented in Fig. 2. 
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Discussion 
We identified 22 studies developing and/or evaluating the performance of clinical 
screening tools aimed to identify men with low BMD: 2 studies assessed the performance 
of 5 guidelines for DXA testing proposed from different entities; 5 studies developed and 
validated 5 new screening tools but of these only 2 were further validated in other 
populations; 12 studies evaluated the performance of OST, 4 assessed the performance 
of MORES and 3 estimated the performance of OSTA. 
Over the last twenty years several tools have been developed aimed to identify 
individuals with low BMD. However, only ten years later, as seen from the present review, 
did these screening instruments start to be validated in men and since then there has 
been a growing interest in their role in this specific population. As far as we know, there 
is only one previous systematic review on this specific topic, dated from 2008 [6]. 
However, subsequently, an important number of new papers were published on this 
topic, justifying the discrepancy between the final number of studies included then and 
now (5 versus 22). 
In general, when positive labelling from test results does not constitute a problem for the 
individual, screening instruments and their cut-offs should prefer to optimise sensitivity 
(i.e. minimizing the likelihood ratio of a negative test result) in the target population, which 
in this case is the general male adult population or the fraction that presents to primary 
health care. Likelihood ratios below 0.1 are considered to provide strong evidence to rule 
out the presence of disease [33]. The LR analysis performed in our review showed that 
negative likelihood ratios for OST and MORES were lower than for OSTA (0.00 versus 
0.14) but also that, in one study, a negative LR of 1.00 was calculated for OST. At the 
elected cut-off by each OST study, negative LR ranged from 0.11 to 0.60, showing that 
most of these thresholds are labelling as healthy many individuals with low BMD. 
Overall, tools screening for low BMD in men seem to have acceptable accuracy at some 
of the tested cut-offs. All the tools identified performed similarly across studies and the 
evidence is not sufficiently robust to determine which one should be adopted in clinical 
practice. However, as OST, OSTA and MORES have been validated more times, and 
include only few clinical variables, they seem to be more appropriate for this purpose, 
especially in the context of a routine clinical examination.  
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For application in White populations, it seems more suitable to select either OST or 
MORES, since OSTA was developed in Asians and validated only once in Whites and 
with low accuracy [19]. One of the studies assessing MORES had very low 
methodological quality. The 3 remaining articles, using a cut-off of MORES≥6, evidenced 
that the good discriminatory capacity showed in the development study diminished in a 
population based validation study [20] and was only slightly lower in an outpatient clinic 
population validation study [22]. OST had a wide range of values proposed as ideal cut-
off (from 2 to 6) but the most often indicated was OST≤2. A similar validity decrease in 
real-life settings was observed as for MORES, with validation in population based studies 
generating lower prediction ability than those conducted in outpatient clinics. MORES is 
based on three clinical variables (age, weight and chronic obstructive pulmonary 
disease) and uses a weighted scale for score calculation. OST comprises only age and 
weight but implies more arithmetic than MORES.  
We only identified one study assessing the accuracy OST in a specific disease 
(rheumatoid arthritis) [31]. This study showed that OST is not accurate in this population, 
as shown by moderate sensitivity and low specificity. 
In this study we used robust methodology following the standards established by the 
PRISMA group for systematic reviews development, namely a detailed definition of 
inclusion and exclusion criteria and rigorous information extraction. However, in contrast 
with the recommendation from this group, for practical reasons we used only one 
database (Medline) for the search. Despite Medline being a widely diffused database, 
we cannot exclude the possibility of selection bias. 
We also assessed the quality of studies based on a modified QUADAS check list. As 
suggested by the author, the QUADAS items should be adjusted for the specific topic of 
the review [9], which we did. The individual quality of studies included varied greatly 
making it difficult to summarize quantitatively the performance of the different screening 
osteoporosis tools developed to identify men with low BMD benefiting from DXA-testing. 
Also, in many cases, there was limited reporting of studies characteristics making formal 
quality assessment more difficult which is in itself a methodological limitation. This 
limitation has already been reported on previous systematic reviews of clinical decision 
rules for low BMD in women [8, 10, 34]. 
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Conclusions 
Overall, tools screening for low BMD in men seem to have acceptable accuracy but no 
tool performed consistently better than other. OST and MORES, for their simplicity, 
accuracy and replication, seem to be more adequate for routine clinical practice.  
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Table 1. Characteristics of Clinical Screening Tools predicting T-scores ≤-2.5   
Author, 
Year 
[Reference] L
o
c
a
l Sample 
characteri
stics 
Men
, n 
Age 
(mean 
or 
range
) Tool 
DXA-
Equipm
ent 
(Model) 
Reference 
Group (age, 
sex, 
population, 
race) 
Anatomic
al site for 
low BMD 
diagnosis 
Sensiti
vity 
Specif
icity Cut-Off AUC LR+ LR- 
Adler et al., 
2003 [24] 
U
S
A
/ 
C
a
n
a
d
a
 
Pulmonary 
and 
rheumatolo
gy clinics 
181 64.3 OST 
Hologic 
(QDR 
4500) 
Manufacture 
reference (LS); 
NHANES 
(TH/FN); other 
characteristics 
not mentioned 
Lumbar 
spine, 
total hip or 
femoral 
neck 
93%        
95%        
83%       
82%        
74% 
66%       
60%        
80%        
74%       
80% 
OST<3                     
OST<2                        
OST<1               
OST<3 (W)               
OST<3 (AA) 
0.836                                                                                                                    
0.848 (W)  
0.800 (AA) 
2.74 
2.38
4.15 
3.15 
3.70 
0.11 
0.08
0.21 
0.24 
0.32 
Lynn et al., 
2005 [25] C
h
in
a
 
Population 
based 
197
0 
73.0 OST 
Hologic 
(QDR 
4500) 
Young adult 
men; Chinese 
Lumbar 
spine, 
total hip or 
femoral 
neck 
NA NA NA 0.774 NA NA 
Kung et al., 
2005 [17] C
h
in
a
 
Population 
based 
356 
65.0 
and 
64.0 
OST
A 
Hologic 
(QDR 
2000) 
Young adult 
men; Chinese 
Lumbar 
spine, 
total hip or 
femoral 
neck 
83%       
72%        
71% 
67%        
65%        
68% 
OSTA≤-1 (FN) 
OSTA≤-1 (LS) 
OSTA≤-1 (AS) 
0.850    
0.790         
0.780 
2.52 
2.06 
2.22 
0.25 
0.43 
0.43 
Li-Yu et al., 
2005 [18] 
P
h
ili
p
p
in
e
s
 
Patients 
referred to 
DXA 
132 62.9 
OST
A 
GE-
Lunar 
(DPX IQ) 
Young adult 
men; Chinese 
Femoral 
neck 
91% 66% OSTA≤-1 0.848 2.68 0.14 
 
Sinnott et 
al., 2006 
[26] 
 
 
U
S
A
 
Afro-
American 
from 
outpatient 
general 
clinic 
128 63.8 OST 
GE-
Lunar 
(NA) 
Young women, 
manufacture 
population, 
White (LS); 
young male, 
manufacture 
population, 
Caucasian 
(TH/FN) 
Total hip 
and 
femoral 
neck 
89%        
89%       
89% 
54%       
64%        
74% 
OST<4                        
OST<3                        
OST<2 
0.890 
1.93 
2.47 
3.42 
0.20 
0.17 
0.15 
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Table 1. Continued   
Author, 
Year 
[Referenc
e] L
o
c
a
l Sample 
characte
ristics 
Men, 
n 
Age 
(mean 
or 
range) Tool 
DXA-
Equipme
nt 
(Model) 
Reference 
Group (age, 
sex, 
population, 
race) 
Anatomic
al site for 
low BMD 
diagnosis 
Sensiti
vity 
Specifi
city Cut-Off AUC LR+ LR- 
Skedros 
et al., 2007 
[27] U
S
A
 
Orthopae
dic clinic 
158 67.5  OST 
GE-
Lunar 
(Prodigy) 
NA 
Lumbar 
spine, total 
hip or 
femoral 
neck 
85% 64% OST<2 0.760 2.36 0.23 
Ghazi et 
al., 2007 
[28] M
o
ro
c
c
o
 
Patients 
referred 
to DXA 
229 62.3 OST 
GE-
Lunar 
(Prodigy) 
Young women, 
Moroccan 
Lumbar 
spine, total 
hip or 
femoral 
neck 
64%        
88%         
64%             
52%          
75%           
54%            
36%             
63%           
40% 
60% 
58%  
60%  
71%  
70%  
73%  
80%  
79%  
81% 
OST<2 (LS)           
OST<2 (TH)            
OST<2 (AS)            
OST<1 (LS)            
OST<1 (TH)            
OST<1 (AS)            
OST<0 (LS)            
OST<0 (TH)            
OST<0 (AS) 
0.660 (LS)   
0.787 (TH)  
0.667 (AS) 
1.60 
2.10 
1.60 
1.79 
2.50 
2.00 
1.80 
3.00 
2.11 
0.60 
0.21 
0.60 
0.68 
0.36 
0.63 
0.80 
0.47 
0.74 
Castrillón 
et al., 2007 
[29] S
p
a
in
 
Outpatie
nt 
general 
clinic 
(with 
suspecte
d 
osteopor
osis) 
67 47.0 OST 
GE-
Lunar 
(DPX L) 
and 
Hologic 
(QDR 
4500) 
Young (sex 
not 
mentioned); 
manufacture 
population 
Lumbar 
spine, total 
hip or 
femoral 
neck 
NA NA OST<3 
0.623 (non 
significant) 
NA NA 
Pongchaiy
akul et al., 
2007 [23] T
a
iw
a
n
 
Populatio
n based 
230 63.4 KKOS 
GE-
Lunar 
(DPX IQ) 
Young men, 
Thai 
population 
Lumbar 
spine or 
femoral 
neck 
94%           
72%                 
73% 
70%       
73%        
73% 
KKOS<-1 
(LS)      
KKOS<-1 
(FN)     
KKOS<-1 
(AS) 
NA 
3.13 
2.67 
2.70 
0.09 
0.38 
0.37 
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Table 1. Continued   
Author, 
Year 
[Reference] L
o
c
a
l Sample 
characteri
stics 
Men, 
n 
Age 
(mean or 
range) Tool 
DXA-
Equipme
nt 
(Model) 
Reference 
Group 
(age, sex, 
populatio
n, race) 
Anatomic
al site for 
low BMD 
diagnosis 
Sensiti
vity 
Specifi
city Cut-Off AUC LR+ LR- 
Shepherd et 
al., 2007 
[15] 
U
S
A
  
Population 
based 
1498 64.2 MORES 
Hologic 
(NA) 
Young 
male, 
NHANES 
population, 
specific for 
race 
Total hip 95% 61% MORES≥6 0.842 2.44 0.08 
Zimering et 
al., 2007 
[14] 
U
S
A
 
Endocrinol
ogy, 
rheumatolo
gy and 
general 
clinics 
197 
(C)   
134 
(AA) 
68.4 (C) 
60.9 (AA) 
Mscore 
Mscoreag
e-weight;      
OST 
Hologic 
(QDR 
4500) 
Young 
male, 
NHANES 
population, 
specific for 
race 
Femoral 
neck 
88%      
88% 
49%     
57% 
Mscore>8 (W)       
Mscore>9 (W) 
0.840 1.73 
2.05 
0.24 
0.21 
85% 50% 
Mscoreage-weight>8 
(W) 
0.810 
1.70 0.30 
85% 58% 
Mscoreage-weight>9 
(W) 2.02 0.26 
        
75% 65% 
Mscoreage-weight>10 
(W) 2.14 0.38 
        100% 69% 
Mscoreage-weight>8 
(AA) 
0.990 
3.23 0.00 
         100% 73% 
Mscoreage-weight>9 
(AA) 3.70 0.00 
         100% 77% 
Mscoreage-weight>10 
(AA) 4.35 0.00 
         75% 68% OST<2 (W) 
0.810 
2.34 0.37 
         75% 59% OST<3 (W) 1.83 0.42 
         85% 51% OST<4 (W) 1.73 0.29 
         100% 83% OST<2 (AA) 
0.990 
5.88 0.00 
         100% 76% OST<3 (AA) 4.17 0.00 
         100% 72% OST<4 (AA) 3.57 0.00 
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Table 1. Continued 
  
Author, 
Year 
[Reference]  L
o
c
a
l Sample 
characterist
ics 
Men, 
n 
Age 
(mean 
or 
range) Tool 
DXA-
Equipme
nt 
(Model) 
Reference 
Group (age, 
sex, 
population, 
race) 
Anatomic
al site for 
low BMD 
diagnosis 
Sensiti
vity 
Specifi
city Cut-Off AUC LR+ LR- 
Lynn et al., 
2008 [30] 
U
S
A
 a
n
d
 
C
h
in
a
 
Population 
based 
4658 
Cauc
asian 
1914 
Chine
se 
65-? OST 
Hologic 
(QDR 
4500) 
Whites: 
young men, 
NHANES 
population, 
white (FN) 
and young 
men, 
manufacture 
population  
(LS) 
Chinese: 
young men, 
Chinese 
population;  
Lumbar 
spine, total 
hip or 
femoral 
neck 
79%     
88% 
49%   
36% 
OST<1                    
OST<2 
Whites:  
0.662 (LS)  
0.823 (TH)   
0.740 (FN)  
0.714 (AS) 
1.55 
1.38 
0.43 
0.33 
       
82%  
91% 
56%   
36% 
OST<1                    
OST<2 
Chinese: 
0.717 (LS) 
0.855 (TH) 
0.849 (FN) 
0.759 (AS) 
1.86 
1.42 
0.32 
0.25 
Scholtissen 
et al., 2009 
[16] 
B
e
lg
iu
m
 a
n
d
 F
ra
n
c
e
 
Population 
Based 
502 69.3 
Age + 
BMI + 
Family 
history 
of 
fracture
s + 
Previou
s 
fracture 
Hologic 
(QDR 
4500) 
and GE-
Lunar 
(Prodigy) 
Young men, 
local 
population 
Lumbar 
spine, total 
hip or 
femoral 
neck 
NA NA NA 0.712 NA NA 
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Table 1. Continued 
  
Author, 
Year 
[Reference] L
o
c
a
l 
Sample 
characteristics 
Men, 
n 
Age 
(mean 
or 
range) Tool 
DXA-
Equipment 
(Model) 
Reference 
Group (age, 
sex, 
population, 
race) 
Anatomical 
site for low 
BMD 
diagnosis 
Sensiti
vity 
Specifi
city Cut-Off AUC LR+ LR- 
Verdijket et 
al., 2009 
[11] 
N
e
th
e
rl
a
n
d
s
 
Outpatient 
general clinic 
64 71.7 
Dutch 
case-find 
instrument 
Hologic 
(QDR 
4500) 
FN: young 
(sex not 
mentioned), 
NHANES 
population; 
LS: young  
(sex not 
mentioned), 
manufacture 
population 
Lumbar 
spine and 
femoral 
neck 
11% 92.7% ≥4 NA 1.51 0.96 
Machado et 
al., 2010 
[19] P
o
rt
u
g
a
l 
Population 
based 
202 63.8 
OSTA and 
OST 
Hologic 
(QDR 
4500) 
FN: young 
(sex not 
mentioned), 
NHANES 
population; 
LS: young 
male, 
manufacture 
population 
Lumbar 
spine, total 
hip or 
femoral 
neck 
47%     
62%     
77%     
85%     
38%     
56%      
74%     
77% 
73%     
64%    
50%     
33%      
82%     
68%     
58%       
43% 
OST<1                    
OST<2                       
OST<3                     
OST<4                      
OSTA<1                    
OSTA<2                       
OSTA<3                     
OSTA<4       
NA 
1.74 
1.72 
1.54 
1.27 
2.11 
1.75 
1.76 
1.35 
0.73 
0.59 
0.46 
0.45 
0.76 
0.65 
0.45 
0.53 
Richards et 
al., 2009 
[31] U
S
A
 Men with 
rheumatoid 
arthritis 
282 66.1 OST 
Hologic 
(NA) and 
Lunar (NA) 
Young male, 
NHANES 
population, 
specific for 
race 
Femoral 
neck and 
total hip 
6%        
18%     
34%      
40%     
58%     
68%       
78%       
84%    
94%     
92%     
80%     
71%     
64%     
53%     
45%      
34%  
OST≤-2                     
OST≤-1                   
OST≤0                      
OST≤1                     
OST≤2                     
OST≤3                     
OST≤4                      
OST≤5 
NA 
1.00 
2.25 
1.70 
1.38 
1.61 
1.45 
1.42 
1.27 
1.00 
0.89 
0.83 
0.85 
0.66 
0.60 
0.49 
0.47 
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Table 1. Continued   
Author, 
Year 
[Referen
ce] L
o
c
a
l Sample 
characteri
stics 
Men, 
n 
Age 
(mean 
or 
range) Tool 
DXA-
Equipme
nt 
(Model) 
Reference 
Group 
(age, sex, 
populatio
n, race) 
Anatomic
al site for 
low BMD 
diagnosis 
Sensiti
vity 
Specifi
city Cut-Off AUC LR+ LR- 
Shepher
d et al., 
2010 [20] U
S
A
 
Population 
based 
2944 63.0 MORES 
Hologic 
(QDR 
4500) 
Young 
male, 
population 
not 
mentioned 
Lumbar 
spine 
58%      
51%      
76%      
60%      
90% 
65%  
67%  
62%   
56%  
50% 
MORES>6 
0.657                      
0.653 (W)                
0.786 (AA)             
0.601 (MA)             
0.648 
(others) 
1.29 
1.55 
2.00 
1.36 
1.8 
0.65 
0.73 
0.39 
0.71 
0.20 
 
 
      
Lumbar 
spine, total 
hip or 
femoral 
neck 
66%      
60%      
79%      
71%      
95% 
68%  
69%  
63%  
59%  
55% 
MORES>6 
0.728     
0.721 (W) 
0.781 (AA) 
0.703 (MA) 
0.675 
(others) 
2.06 
1.94 
2.14 
1.73 
2.11 
0.50 
0.58 
0.33 
0.49 
0.09 
Vilaseca 
et al., 
2011 [12] S
p
a
in
 
Outpatient 
rheumatolo
gy and 
surgery 
clinics 
49 
+ 
52 
56.5  
and  
72.7 
Guideline
s AETIM, 
NOF 
2010, 
WHO, 
WHO 
2003 
Hologic 
(QDR 
1000) 
Sex or age 
not 
mentioned; 
Spanish 
population 
Lumbar 
spine and 
femoral 
neck 
60% 
67% 
 
100% 
100%  
 
100% 
83%   
 
80%  
50%     
91% 
67% 
 
32% 
8% 
 
33% 
25% 
 
56% 
61% 
AETIM                              NA    
6.67 
2.06 
0.44 
0.49 
NOF                               NA
1.47 
1.09 
 
0.00 
0.00 
WHO                            NA
1.49 
1.11 
0.00 
0.68 
WHO 2003 NA 
1.82 
1.28 
0.36 
0.82 
Fransisk
a et al., 
2012 [21] 
In
d
o
n
e
s
ia
 
NA 113 71.0 
MORES; 
OST 
NA NA NA 100% 7% MORES≥6 0.535 1.08 0.00 
         74% 41% OST≤2 0.574 1.25 0.63 
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Table 1. Continued   
Author, 
Year 
[Referen
ce] L
o
c
a
l Sample 
characterist
ics 
Men, 
n 
Age 
(mean 
or 
range) Tool 
DXA-
Equipme
nt 
(Model) 
Reference 
Group (age, 
sex, 
population, 
race) 
Anatomical 
site for low 
BMD 
diagnosis 
Sensitivi
ty 
Specifi
city Cut-Off AUC LR+ LR- 
Richards 
et al., 
2013 [32] U
S
A
 
Outpatient 
general clinic 
518 66.0 OST 
Hologic 
(NA) and 
Lunar 
(NA) 
young male, 
NHANES 
population, 
specific for race 
Lumbar 
spine, total 
hip or 
femoral neck 
7%               
42%        
62%       
75%        
86%      
90% 
98%    
85%     
65%     
41%    
32%    
23% 
OST≤-3                         
OST≤-0                        
OST≤3                         
OST≤5                         
OST≤6                        
OST≤8    
0.720 
(W) 
3.50 
2.80 
1.77 
1.27 
1.26 
1.17 
0.95 
0.68 
0.58 
0.61 
0.44 
0.43 
 
 
       
10%          
14%          
45%          
NA            
70%        
83% 
99%   
99%    
69%   
NA     
36%    
30% 
OST≤-3                        
OST≤-0                        
OST≤3                         
OST≤5                        
OST≤6                        
OST≤8    
0.580 
(AA)
10 
14 
1.45 
NA 
1.04 
1.19 
0.91 
0.87 
0.80 
NA 
0.83 
0.57 
Cass et 
al., 2013 
[22] U
S
A
 
Outpatient 
general clinic 
346 70.2 MORES 
Hologic 
(QDR 
4500) 
and GE-
Lunar 
(iDXA) 
young women, 
NHANES 
population 
Femoral 
neck or total 
hip 
80% 70% 
MORES
≥6 
0.82 2.67 0.29 
DXA, Dual-energy X-ray absorptiometry; BMD, bone mineral density; AUC, Area under the curve; LR+, positive likelihood ratio; LR-, negative likelihood ratio; OST, 
Osteoporosis screening tool; W, Whites; AA, African-American; NA, Non-available; OSTA, osteoporosis screening tool for Asians; FN, femoral neck; LS, lumbar spine; AS, 
any site; USA, United States of America; TH, total hip; KKOS, Khon Kaen osteoporosis study; MORES, male osteoporosis risk estimation score; NHANES, National health 
and nutrition examination study; MA, Mexican American. 
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Table 2. Characteristics of Clinical Screening Tools predicting T-scores ≤-2.0   
Author, 
Year 
[Referen
ce] L
o
c
a
l Sample 
characteristic
s 
Men, 
n 
Age 
(mean 
or 
range) Tool 
DXA-
Equipme
nt 
(Model) 
Reference 
Group (age, 
sex, 
population, 
race) 
Anatomic
al site for 
low BMD 
diagnosis 
Sensiti
vity 
Specifi
city Cut-Off AUC LR+ LR- 
Adler et 
al., 2003 
[24] U
S
A
/ 
C
a
n
a
d
a
 Pulmonary 
and 
rheumatology 
clinics 
181 64.3  OST 
Hologic 
(QDR 
4500) 
Manufacture 
reference (LS); 
NHANES 
(TH/FN); other 
characteristics 
not mentioned 
Lumbar 
spine, total 
hip or 
femoral 
neck 
74%            
69%          
62% 
72%       
82%        
89% 
OST<3     
OST<2       
OST<1 
0.815 
2.64 
3.83 
5.64 
0.36 
0.38 
0.43 
Li-Yu et 
al., 2005 
[18] 
P
h
ili
p
p
in
e
s
 
Patients 
referred to 
DXA 
132 62.9  OSTA 
GE-
Lunar 
(DPX IQ) 
Young adult 
men; Chinese 
Femoral 
neck 
72% 69% OSTA≤-1 0.754 2.32 0.41 
Sinnott 
et al., 
2006 [26] U
S
A
 Afro-American 
from outpatient 
general clinic 
128 63.8 OST 
GE-
Lunar 
(NA) 
Young women, 
manufacture 
population, 
Whites (LS); 
young male, 
manufacture 
population, 
Whites (TH/FN)  
Total hip 
and 
femoral 
neck 
83%     
78%     
71% 
57%       
68%       
76% 
OST<4     
OST<3      
OST<2 
0.830 
1.93 
2.43 
2.96 
0.30 
0.32 
0.38 
Skedros 
et al., 
2007 [27] U
S
A
 
Orthopaedic 
clinic 
158 67.5  OST 
GE-
Lunar 
(Prodigy) 
NA 
Lumbar 
spine, total 
hip or 
femoral 
neck 
76% 67% OST<2 0.750 2.30 0.36 
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Table 2. (continued)   
Author, 
Year 
[Referen
ce] L
o
c
a
l Sample 
characteristi
cs 
Men, 
n 
Age 
(mean 
or 
range) Tool 
DXA-
Equipmen
t (Model) 
Reference Group 
(age, sex, 
population, race) 
Anatomical 
site for low 
BMD 
diagnosis 
Sensiti
vity 
Specifi
city 
Cut-
Off AUC LR+ LR- 
Lynn et 
al., 2008 
[30] 
U
S
A
 a
n
d
 C
h
in
a
 
Population 
based 
4658 
Cauc
asian 
+ 
1914 
Chine
se 
65-? OST 
Hologic 
(QDR 
4500) 
Chinese: young 
men, Chinese 
population; 
Whites: young 
men, NHANES 
population, Whites 
(FN) and young 
men, manufacture 
population (LS) 
Lumbar 
spine, total 
hip or 
femoral neck 
NA NA NA 
Caucasian:  
0.648 (LS) 
0.745 (TH) 
0.710 (FN) 
0.695 (AS) 
NA NA 
NA NA NA 
Chinese: 
0.694 (LS) 
0.791 (TH) 
0.758 (FN) 
0.724 (AS)  
NA NA 
DXA, Dual-energy X-ray absorptiometry; BMD, bone mineral density; AUC, Area under the curve; LR+, positive likelihood ratio; LR-, negative likelihood ratio; USA, United States 
of America; OST, Osteoporosis screening tool; LS, lumbar spine;  NHANES, National health and nutrition examination study; TH, total hip; FN, femoral neck; OSTA, osteoporosis 
screening tool for Asians; NA, Non-available; AS, any site. 
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Table 3. Characteristics of Clinical Screening Tools predicting T-scores ≤ -1.0   
Author, 
Year 
[Referenc
e] L
o
c
a
l Sample 
characterist
ics 
Men, 
n 
Age 
(mean or 
range) Tool 
DXA-
Equipmen
t (Model) 
Reference 
Group (age, 
sex, 
population, 
race) 
Anatomical 
site for low 
BMD 
diagnosis 
Sensit
ivity 
Specifi
city Cut-Off AUC  LR+ LR- 
Elliot et 
al., 1993 
[13] 
 
N
e
w
 
Z
e
a
la
n
d
 
 
Population 
based 
 
126 
 
20-82 
 
Weight + 
inactivity 
 
GE-Lunar 
(DPX 4) 
 
BMD in the 
lower third of 
the age 
matched 
normal range 
Lumbar 
spine 
83% 46% 0.054 NA 1.54 0.37 
     
Age + 
Weight + 
family history 
+ inactivity + 
weekly 
calcium 
  
Femoral 
neck 
87% 45% 0.040 NA 1.58 0.29 
Vilaseca 
et al., 2011 
[12] S
p
a
in
 
Outpatient 
rheumatolog
y and 
surgery 
clinics 
49    
+    
52 
56.5 and 
72.7 
Guidelines 
from AETIM, 
NOF 2010, 
WHO and 
WHO 2003 
Hologic 
(QDR 
1000) 
Sex or age 
not 
mentioned; 
Spanish 
population 
Lumbar 
spine and 
femoral neck 
18% 
43% 
92%  
75% 
AETIM NA 
2.25                  
1.72 
0.89 
0.76 
         
79% 
97% 
39%  
17% 
NOF NA 
1.30                        
1.17 
0.54 
0.18 
         
76% 
83% 
39%  
42% 
WHO NA 
1.25 
1.43 
 
0.62 
0.40 
         
68% 
47% 
68%  
75% 
WHO 
2003 
NA 
2.13 
1.88 
0.47 
0.71 
             
  
47 
 
             
  
 
Table 3. Continued   
Author, 
Year 
(Reference) L
o
c
a
l 
Sample 
characteristics 
Men, 
n 
Age 
(mean 
or 
range) Tool 
DXA-Equipment 
(Model) 
Reference 
Group (age, 
sex, 
population, 
race) 
Anatomical 
site for low 
BMD 
diagnosis 
Sensi
tivity 
Speci
ficity Cut-Off AUC LR+ LR- 
Richards et 
al., 2009 
[31] U
S
A
 Men with 
rheumatoid 
arthritis 
282 66.1 
Valid
ation 
of 
OST 
Hologic (not 
mentioned) and 
Lunar (not 
mentioned) 
Young male, 
NHANES 
population, 
specific for 
race 
Femoral 
neck and 
total hip 
7% 98% OST≤-2 NA 3.50 0.94 
         13% 99% OST≤-1  13 0.88 
         27% 90% OST≤0  2.7 0.81 
         35% 79% OST≤1   1.67 0.82 
         46% 74% OST≤2   1.77 0.73 
         57% 65% OST≤3  1.63 0.66 
         64% 54% OST≤4  1.39 0.67 
                  73% 42% OST≤5   1.26 0.64 
DXA, Dual-energy X-ray absorptiometry; BMD, bone mineral density; AUC, Area under the curve; LR+, positive likelihood ratio; LR-, negative likelihood ratio; NA, Non-
available; AETIM, Agencia de Evaluación de Tecnologías e Investigación  Médicas; NOF, National Osteoporosis Foundation; WHO, World Health Organization; USA, 
United States of America; OST, Osteoporosis screening tool; NHANES, National health and nutrition examination study. 
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Papers identified through electronic database searching 
N = 1484 
Full Text Screening 
N = 37 
Excluded papers from titles and 
abstract screening 
N = 1447 
 Language(N=45) 
 Study type (N=136) 
 Population (N= 430) 
 Intervention (N=836) 
Studies Included 
N = 22 
Excluded papers from full text 
screening 
N = 15 
 Population (N=4) 
 Outcome (N=1) 
 No performance 
reported (N=5) 
 No validation (N=3) 
 Systematic reviews 
without new data 
(N=2) 
Figure 1. Flowchart of included studies. 
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Figure 2. Methodological quality of 22 included studies according to a modified QUADAS checklist. 
QUADAS, Quality assessment tool for diagnostic accuracy studies; BMD, Bone mineral density; DXA, 
Dual-energy X-Ray absorptiometry. 
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CHAPTER II 
 
Upper arm circumference measurement improves screening for 
low bone mineral density in men 
Romana Vieira, Milton Severo, Carla Lopes, Raquel Lucas  
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Abstract 
Objectives: To develop and validate a simple clinical screening tool (EPIPOST) able to 
identify men with higher probability of having low bone mineral density (BMD) who may 
benefit from dual-energy X-ray absorptiometry (DXA) testing and to compare its 
discriminatory ability with two other osteoporosis screening tools in men (OST and 
MORES), after calibration for our population. Methods: As part of EPIPorto population-
based study among adults, 147 men aged between 40 and 65 years were assessed. 
Age, height, weight, body mass index and several body circumferences were recorded 
by trained observers. DXA whole-body scans were performed for BMD assessment. For 
the calibration of OST and MORES, new regression parameters were estimated for each 
risk factor included accounting for their prevalence and also for the prevalence of low 
BMD in our population. For EPIPOST development, the different anthropometric 
variables were tested using logistic regression models to predict low BMD. EPIPOST 
validation was done by the leave-one-out cross-validation method. The overall fit and 
discriminatory capacity of the different models were assessed by direct comparison of 
the observed and expected prevalences of low BMD by quartiles of each score, Hosmer-
Lemeshow “goodness-of-fit” test and area under the receiver operating characteristic 
(ROC) curve. Finally, likelihood ratios (LR) were calculated to select the ideal cut-off for 
each model. Results: Calibration maintained the discriminatory capacity of OST and 
MORES (AUC of 0.73 and 0.75, respectively) and improved the fit. The EPIPOST 
included only upper arm circumference and showed better discriminatory capacity (AUC 
0.76).  For predicting low BMD, OST≤2 had a sensitivity of 100% and a specificity of 
8.2%; MORES>-2 had a sensitivity of 93.9% and a specificity of 30.6%; EPIPOST>-2 
had a sensitivity of 98.0% and a specificity of 18.6%. The LR analysis showed that 
EPIPOST had higher discriminative ability across different risk levels (LR range of 0.1 to 
18.4, compared to 0.0 to 2.4 with OST and 0.2 to 2.8 with MORES). Conclusion: 
Calibration of OST and MORES improved the fitting of both models to our population 
data and maintained their discriminatory ability to identify men with low BMD. The newly 
developed tool, EPIPOST, is easier to execute in clinical practice and performed similarly 
to OST and MORES in terms of overall accuracy while showing a wider range of 
discriminatory ability.   
Keywords: Men, Bone Density, Clinical Prediction Rule, Sensitivity and Specificity, 
Screening. 
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Introduction 
Lifetime risk of osteoporotic fracture is higher in women [1]. However, evidence shows 
that case fatality rate after osteoporotic fracture is higher in men [2-4]: the relative risk of 
dying within 1 year after hip fracture versus controls has been estimated in 4.2 in men 
and 3.3 in women below 75 years of age [5]. Nevertheless, comparatively little attention 
to the diagnosis or treatment of male osteoporosis has been given [6], even though the 
early recognition of osteoporosis in men may also have key importance for the disease 
burden in terms of years of life lost. 
The World Health Organization (WHO) recommends the identification of individuals 
eligible for antiresorptive treatment based on a comprehensive fracture risk assessment, 
namely with a dedicated tool (FRAX™). Nevertheless, bone mineral density (BMD) 
assessment by dual-energy X-ray absorptiometry (DXA) remains the gold standard 
method for the diagnosis of osteoporosis [7] and BMD is the strongest objectively 
measured determinant of bone strength accounting for 60-70% of its variation [8]. 
Because of that, BMD determination is still a cornerstone of clinical practice, not only to 
assess fracture risk but also for selecting patients for treatment and to evaluate their 
subsequent response [9].  
Even though DXA equipment is available in many settings, it was estimated that, to 
detect one previously undiagnosed case of osteoporosis, the number needed to screen 
by BMD testing is high in the population with no clinical risk factors and even higher in 
men than women (6 women aged 65 years old or more, 13 men aged 65 years old or 
more and 10 men aged 70 years old or more) [10]. This calls for a targeted case finding 
strategy rather than population-based screening in order to maximize yield and cost-
effectiveness [9]. Simple tools able to identify men at higher risk of osteoporosis using 
only easily obtained clinical data facilitate case ascertainment namely in primary 
healthcare settings. 
Several clinical tools have been developed and validated in women [11-15] based on 
variables like age and anthropometric measures [16-19]. The Osteoporosis Self-
assessment Tool (OST) was originally developed in women [11] but has also been 
validated in men [20-22]. Other tools have been specifically developed and validated for  
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men [23-27]. Because of their strong association with bone fragility, age and weight [16] 
have been included in most of these parsimonious models. However, risk factors for 
bone fragility are likely to operate differently across genders: with ageing, women tend 
to experience accelerated bone loss after menopause whereas men have a more 
gradual one [28]; also weight probably translates different risks because of sexual 
dimorphism related to body composition, with the ratio of lean to fat being much greater 
in males than females [29].  
We hypothesised that the inclusion of easily accessible anthropometric measures that 
reflect sexual dimorphism of body composition would have similar accuracy to age and 
weight in predicting low bone mineral density in men, when compared to previously 
developed tools. 
Our objective was to develop and validate a simple clinical screening tool (EPIPOST) 
able to identify men with higher probability of having low BMD who may benefit from 
DXA-scan testing, based on variables easily obtained, taking into account sexual 
dimorphism. We also compared the performance (discrimination) of our tool with the 
ones of the two most validated osteoporosis screening tools in men [OST and MORES 
(male osteoporosis risk estimation score)], after calibration for our population.  
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Methods 
Participants 
In 2010/2011, we evaluated 147 men aged between 40 and 65 years old. They are a 
subsample selected randomly and stratified by sex and age within the EPIPorto cohort 
which is a sample of urban dwellers in Porto. Briefly, participants were selected between 
1999 and 2003, using random digit dialling of landline telephones to select households. 
The vast majority of houses (>95%) had a landline telephone at the time of this 
procedure. We used a table of random numbers to define the last four digits that are 
specific to individual houses, assuming the local prefix codes to limit the universe to the 
city of Porto. Within each household, we selected a permanent resident, aged 18 years 
or more, using simple random sampling. We considered a refusal if the person explicitly 
said that he/she did not want to participate and refusals were not substituted within the 
same household. The proportion of participation was 70%, as previously described [30]. 
Data collection 
Trained interviewers administered a structured questionnaire comprising questions on 
sociodemographic, clinical and behavioural characteristics.  
Anthropometric measurements were performed, according to standard procedures, after 
an overnight fast, with the participant wearing light clothing and no footwear [31]. Body 
weight was measured to the nearest 0.1 kg using a digital scale, and height was 
measured to the nearest centimetre in the standing position using a wall stadiometer. 
Body mass index (BMI) was calculated as weight (kg) divided by squared height (m2). 
Waist circumference was measured midway between the lower limit of the rib cage and 
the iliac crest. Abdominal circumference was measured at the umbilicus level with the 
individual at full expiration. Measurements were taken to the nearest 0.1 cm. Hip 
circumference was measured in orthostatic position considering the highest value at the 
gluteus level to the nearest 0.1 cm. Right mid-thigh circumference was measured to the 
nearest 0.1 cm with the individual in sitting position, with the leg at 90º flexion, at the 
midpoint between the inguinal line and the superior patellar border. Relaxed upper arm 
circumference was measured at the non-dominant arm at the mid-point between scapula 
acromial apophysis and the radius head. The arm was relaxed along the body. The tape 
was tightly positioned without pressure, parallel to the floor. Measurements were taken 
to the nearest 0.1 cm. Flexed upper arm circumference was measured at the non-
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dominant arm in the highest point. The tape was tightly positioned without pressure, 
parallel to the floor. Measurements were taken to the nearest 0.1 cm. 
DXA whole-body scans were performed for BMD assessment (QDR 4500A, Hologic, 
Bedford, MA). A single DXA operator conducted all scans. We used T-scores as a 
relative measure of BMD as recommended by WHO. T-score is a value for BMD 
expressed as the number of standard deviations (SD) by which an individual 
measurement differs from the mean value for healthy adult female population aged 30 
years [32].  Definition of osteoporosis was refined with the femoral neck being proposed 
as the standard measurement site and the reference population being the mean and SD 
values in young women obtained from the NHANES III study [33, 34]. Participants were 
classified as normal (T-score≥-1.0), osteopenic (-1.0>T-score>-2.5) and osteoporotic (T-
score≤ -2.5) [35]. Finally, we dichotomized T-score value at -1.0 with participants with a 
T-score<-1.0 being classified as having low bone mineral density (osteopenia + 
osteoporosis). 
Statistical analysis 
Student’s t-test was computed to compare the distributions of continuous variables 
between two independent samples. All p-values were two sided, and the significance 
level was set at 5%. 
For the calibration of OST and MORES, new regression parameters were estimated for 
each risk factor included accounting for their prevalence and also for the prevalence of 
low BMD in our population, thereby optimizing the fit of the resulting model to the 
observed data. The calibrated parameters are presented in Appendix 1. For the 
evaluation of fit we performed a direct comparison of the observed and expected 
prevalences of low BMD by quartiles of each score and also applied the Hosmer-
Lemeshow “goodness-of-fit” test before and after calibration for each model. 
For the new tool (EPIPOST) development we first performed a bivariate analysis for the 
association of low bone mineral density and the candidate predictive variables. Then we 
ran logistic regression models using the forward method to predict low bone mineral 
density. The final model was selected taking into account the clinical simplicity, face 
validity, discriminatory ability based on area under the receiver operating characteristic 
(ROC) curve, and overall fit (Hosmer-Lemeshow “goodness-of-fit” test). 
58 
 
Areas under the ROC curves (AUC) were calculated to assess the discriminatory 
capacity of the calibrated and new tools to differentiate between individuals with and 
without low BMD. DXA-derived T-score categories (low BMD if T-score<-1.0 and normal 
BMD if T-score≥-1.0) were used as the state variable for this. Finally, likelihood ratios 
(LR) were calculated to select the ideal cut-off for each model.  
Validation was done by the leave-one-out cross-validation method. Briefly, the equation 
was trained on 147 minus 1 individuals, and the trained equation was then used to test 
the individual that had been left out. This process was repeated until every individual in 
the dataset had been used once as an un-seen test individual. The agreement estimated 
by leave-one-out cross-validation was then compared with the one estimated using the 
whole sample to evaluate possible over-fitting. 
Statistical analysis was performed using IBM SPSS Statistics 21 and RStudio statistical 
software. 
  
59 
 
Results 
A total of 147 men were included in the current analysis with a mean age of 54 years. 
Characteristics of the study participants are listed in Table 1 as well as their stratification 
by BMD category: participants with low BMD were lighter and had smaller overall 
circumferences than those with normal BMD. 
The prevalence of osteoporosis was 0.7% (n=1) at the femoral neck and 13.6% (n=20) 
at the lumbar spine. Considering the presence of T-score≤-2.5 at least in one of the two 
sites, the overall prevalence of osteoporosis was 14.2% (n=21). Low BMD at the femoral 
neck was present in 49 participants (33.3%).  
Weight, BMI and all circumferences were significantly associated with low BMD in 
bivariate analysis (Table 2). When the significant variables were entered into logistic 
regression model with forward selection method, the final model retained only relaxed 
upper arm circumference for low BMD prediction. In fact, when BMI and circumferences 
were adjusted for relaxed upper arm circumference, their statistical significance 
observed in crude analysis was lost. Therefore, the final estimated equation was 
EPIPOST ~ 11.6 - 0.39 * (relaxed upper arm circumference). 
As shown in Figure1, calibration of OST and MORES enhanced the similarity between 
the observed prevalence of low BMD in our population and that predicted by the models 
in each score quartiles. Although OST and MORES scores relate differently to BMD (low 
BMD is associated with low OST score and high MORES score), to simplify the 
interpretation of the results, we inverted the OST equation so that higher OST scores 
relate also to low BMD. The fit of both screening tools tested by the Hosmer-Lemeshow 
goodness-of-fit test improved after calibration despite maintenance of overall accuracy 
as measured by the AUC value (Table 3). Mean (SD) OST score was 2.49 (1.51) and 
after calibration was -0.90 (1.10). Mean (SD) MORES score was 3.49 (3.04) and after 
calibration was 0.82 (0.98). Estimated parameters after calibration for both OST and 
MORES are presented in Appendix 1. 
In terms of global accuracy comparison, the two calibrated models and the newly 
developed one had similar results. However, even though only marginally, EPIPOST had 
the highest AUC (0.76). The likelihood ratios (LR) analysis (Table 4) showed that for 
OSTcalibrated the ideal cut-off to rule out the presence of low BMD was 2, meaning that 
individuals scoring ≤2 should be referred to DXA-scan testing. For both MOREScalibrated 
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and EPIPOST the equivalent cut-off was -2, meaning that individuals scoring >-2 should 
undergo DXA-scan testing. However, the LR associated with these cut-offs were not the 
same: OST had the cut-off with lowest LR (0.0) followed by EPIPOST (0.1) and finally 
MORES (LR 0.2). Moreover, the range of LR values obtained with EPIPOST showed 
that our tool had higher discriminative ability across different risk levels (0.1 to 18.4, 
compared to 0.0 to 2.4 with OST and 0.2 to 2.8 with MORES). 
An OST≤2 had a sensitivity of 100% and a specificity of 8.2% to predict low BMD. A 
MORES>-2 had a sensitivity of 93.9% and a specificity of 30.6%. An EPIPOST>-2 had 
a sensitivity of 98.0% and a specificity of 18.6%. The EPIPOST positive LR for that cut-
off was 1.20 and the negative LR was 0.11.   
The leave-one-out cross-validation showed that the agreement between the observed 
and predicted values was 73.3% in the training sample and 71.2% across validation 
samples. Chance-corrected agreement, measured by Cohen’s kappa coefficient, was 
0.35 and 0.28, respectively. 
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Discussion 
We showed that calibration improved the OST and MORES fitting to our population and 
that individuals scoring OST≤2 and MORES>-2 should undergo DXA-scan testing. OST 
proved to have higher sensitivity than MORES (100% versus 93.9%) despite lower 
specificity (8.2% versus 30.6%) in identifying men with low BMD that should be evaluated 
with DXA testing. We also developed a new low BMD screening tool, EPIPOST, 
specifically for male sex. This new tool had even better discriminatory ability than OST 
and MORES (AUC 0.76 versus 0.73 and 0.75, respectively) and, at scores greater than 
-2, improved sensitivity regarding to MORES (98.0% versus 93.9%) and better specificity 
than OST (18.6% versus 8.2%). 
As osteoporosis remains asymptomatic until fracture occurs, bone mass assessment 
and early low bone mass diagnosis is a cornerstone of fracture prevention. Although 
clinical assessment tools are not meant to diagnose osteoporosis they do assist 
clinicians in identifying asymptomatic individuals likely to have low bone mass and, thus, 
they are an important part of population approaches to the prevention of osteoporotic 
fractures. Earlier studies on osteoporosis screening tools focused their attention on older 
men with higher risk of osteoporosis. However, it is precisely in men over the age of 70 
that immediate DXA screening proves to be more cost-effective, as supported by clinical 
guidelines, thereby limiting the need for prior clinical decision rules. Our objective was 
on the one hand to determine the clinical utility of clinical decision rules in a younger 
range of male subjects (40 to 65) and, on the other hand, to assess their capacity of 
identifying earlier stages of decreased bone mass when preventive measures may be 
more effectively applied.  
We calibrated and evaluated the performance of the two most validated screening tools 
for the detection of low bone mineral density in men (OST and MORES). Risk prediction 
scores are developed and validated in target populations with a certain risk level. 
Independently of its performance in terms of overall accuracy, the discriminative power 
of each score in predicting the status of each individual in different populations may be 
increased through its calibration to the target population of interest. Regarding MORES, 
the coefficient for chronic obstructive pulmonary disease (COPD) was not calibrated as 
the prevalence of this condition in our population was very low (n=3). Also, since MORES 
includes age classes, with the highest risk being associated to age≥75 years, the fact 
that our population is younger than 65 years old probably affected MORES discriminatory 
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capacity and did not take advantage of the its whole spectrum of predictive ability. Still, 
calibration of both OST and MORES permitted the improvement of the agreement 
between observed and estimated prevalences of low BMD across scores’ quartiles. As 
far as we know, no other previous study has been conducted to accomplish this 
objective.  
Despite the achievement of a better discriminatory performance after calibration of these 
two models, we still found pertinent to develop a model that took into consideration 
sexual body composition differences and that did not include weight – a variable which 
needs either measurement in light indoor clothing or which is subject to documented self-
reporting limitations. Although we cannot estimate the accuracy of EPIPOST in women, 
its generalization to females should not be straightforward as it is known that adult males 
have greater total lean mass and a lower fat mass than females and that these whole-
body differences are complemented by major differences in tissue distribution, such as 
greater arm muscle mass in adult males [29].  
In developing the best fitting model, we found that relaxed upper arm circumference 
predicted better the presence of low BMD than any other variable. Regardless of its 
statistical significance, upper arm circumference has also face validity as it has been 
suggested as a proxy of BMI and a good indicator of lean body mass depletion [36]. It 
has also the advantage of being easy to measure in clinical practice, requiring one piece 
of very portable equipment, no need for calibration and little effort from the patient, 
making it particularly suitable for the hasty routine of a clinical practice setting. The 
incorporation of variables that accounted not only for the discrimination performance and 
goodness-of-fit but also face validity, with known clinical value and easily obtained in a 
real scenario, was a major concern in our model development.  
Comparing the performance of EPIPOST, OST and MORES we found that they had 
similar discriminatory performance as assessed by AUC but it is important to notice that 
EPIPOST performed slightly better and showed a wider range of likelihood ratios for 
different cut-offs. The likelihood ratios indicate by how much a given diagnostic test result 
will raise or lower the pretest probability of the target disorder. Likelihood ratios>1.0 
increase the probability that the target disorder is present and likelihood ratios<1.0 
decrease the probability of the target disorder. A rule to interpret likelihood has been 
proposed with values of >10 or <0.1 being considered to provide strong evidence to rule  
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in or out, respectively, the presence of the specific condition [37]. OST and EPIPOST 
revealed LR<0.1 at cut-offs 2 and -2, respectively, but only EPIPOST had a cut-off 
(EPIPOST>1) associated with a LR>10 (18.4) meaning that an individual scoring 
EPIPOST>1 most certainly has low BMD. 
This study has the advantage of being population-based which makes generalization of 
the results more valid. Another advantage relates to the sample age range: men less 
than 65 years old represent a population with less clearly defined criteria for DXA-scan 
testing, in which rapid tools directing the selection for further examination are particularly 
useful. Many clinical societies and governmental health authorities defend global testing 
for men aged more than 70 years with the remaining staying in a grey zone [38]. Femoral 
neck was selected as reference site in conformity with the recommendation of the 
International Osteoporosis Foundation and also because it is has high predictive value 
for hip fracture risk and there is wider experience with this site [9].  
The interpretation of our results must take into account several limitations. The study 
was conducted in a relatively small number of men, which limits statistical power: our 
sample of approximately 150 participants allowed for the estimation of a prevalence of 
50%, with 8% precision at a 0.05 confidence level with 80% power. Because the sample 
was randomly selected with no clinical exclusion criteria it is possible that some 
osteoporotic patients have secondary causes. However, the prevalence of such causes 
in our cohort is likely to be very small with limited expected impact in the results. For 
example, none of the individuals in our sample reported to have rheumatoid arthritis. 
Another limitation is that we did not perform validation with an external population. 
However, we assessed internal validity by leave-one-out cross-validation which showed 
acceptable concordance.  
Direct comparisons of our results with those of previous studies validating OST and 
MORES are difficult to make due to many methodological differences across studies in 
terms of sample characteristics (population source, age, race), bone mass assessment 
(DXA equipment and quality assessment), low bone mass diagnosis (reference 
population for T-score calculation, anatomical site selected). Nevertheless, a previous 
study assessing the performance of MORES in diagnosis osteoporosis at the hip 
reported an AUC of 0.842 and a sensitivity 95% of and a specificity of 61% with scores 
equal or higher than 6. This was a population based study including men older than 50  
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years with a mean age 64.2 years [23]. The performance of MORES at the lumbar spine 
in white men was lower with an AUC of 0.653 and a sensitivity of 51% and a specificity 
of 67% with a MORES≥6 [39]. Another study validating MORES in a clinical setting 
showed an AUC of 0.82 with a sensitivity of 80% and a specificity of 70%, at the same 
score, in diagnosing men with hip osteoporosis [27]. Only the latter was performed taking 
as reference for T-score calculation young white women from the NHANES population, 
the recommended gold standard which we used in our study. 
The validation of OST has been performed more times than MORES. Zimering et al. [25] 
tested OST in a clinical sample and reported an AUC of 0.81 and a sensitivity of 85% 
and specificity of 51% at a cut-off of 4 in diagnosing osteoporosis at the femoral neck in 
white men. A population based study from Lynn et al. [22] testing OST to diagnose 
osteoporosis in white men at lumbar spine, femoral neck or total hip reported an AUC of 
0.714 and a sensitivity of 88% and a specificity of 36% at scores equal or lower than 2. 
Another population based study from Portugal [40] calculated an AUC of 0.632 with a 
sensitivity of 77% and a specificity of 50% for OST<3 in diagnosing osteoporosis at either 
the femoral neck or the lumbar spine. Richards et al. [21] proposed an OST index of 6 
or lower predicting osteoporosis at lumbar spine, femoral neck or total hip in white men 
from a clinical population with a sensitivity of 86% and a specificity of 32%. The reported 
AUC was 0.72. The different cut-offs proposed for OST in different settings may be 
regarded as confusing and highlight the need for the calibration of the scores for each 
population prior to their generalized use.  
In this study we developed and validated a simple tool to select men for DXA testing 
using only relaxed upper arm circumference, which is more suitable than body weight for 
clinical examination, particularly following routine blood pressure determination. Our tool 
was similar to previously developed scores in terms of overall accuracy but showed a 
wider range of discriminatory ability.   
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Table 1. Study sample characteristics: overall and by bone mineral density 
category 
Baseline 
Characteristics 
Men     
  
(mean, sd) (n = 147) 
Low BMD              
(n = 49) 
Normal BMD           
(n = 98) 
p-value 
Age (years)  53.6 (7.03) 54.8 (6.96) 52.9 (7.02) 0.123 
Weight (Kg) 77.8 (12.97) 70.9 (10.81) 81.3 (12.61) <0.001 
Height (cm) 171.4 (7.16) 170.3 (6.14) 172.0 (7.59) 0.180 
BMI  (kg/m2) 26.4 (3.66) 24.4 (3.04) 27.4 (3.53) <0.001 
Circumferences     
Relaxed upper arm 
(cm) 
31.7 (3.01) 29.8 (2.81) 32.6 (2.67) <0.001 
Flexed upper arm 
(cm) 
32.6 (3.00) 30.8 (2.71) 33.5 (2.73) <0.001 
Waist (cm) 96.3 (10.41) 90.7 (9.55) 99.2 (9.67) <0.001 
Abdomen (cm) 97.8 (10.23) 92.3 (9.24) 100.5 (9.62) <0.001 
Hip (cm) 99.5 (6.74) 96.2 (5.64) 101.2 (6.66) <0.001 
Thigh (cm) 52.2 (3.90) 50.0 (3.56) 53.3 (3.60) <0.001 
DXA     
Lumbar Spine BMD 
(g/cm2) 
− 0.969 (0.140) 0.889 (0.127) 1.009 (0.130) <0.001 
Lumbar Spine T-
score 
1.071 (1.246)   − 1.785 (1.139) − 0.720 (1.147) <0.001 
Femoral Neck BMD 
(g/cm2) 
0.794 (0.1243 0.662 (0.050) 0.859 (0.094) <0.001 
Femoral Neck T 
score 
 − 0.537 (1.036) − 1.636 (0.417) 0.012 (0.784) <0.001 
BMI, body mass index; DXA, Dual-energy X-ray absorptiometry. 
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Table 2. Crude and Adjusted Analysis of Age and different anthropometric 
variables and low bone mineral density 
  Crude Analysis Model 1* 
Variables OR 95% CI OR 95% CI 
Age 1.04 0.99-1.09 1.03 0.98-1.09 
Weight 0.92 0.89-0.96 0.98 0.93-1.04 
Height 0.97 0.92-1.02 1.01 0.95-1.06 
BMI 0.73 0.64-0.84 0.90 0.72-1-13 
Relaxed UAC 0.68 0.57-0.79   
Waist 0.91 0.87-0.95 0.97 0.91-1.04 
Abdomen 0.91 0.87-0.95 0.98 0.91-1.05 
Hip 0.87 0.82-0.93 0.98 0.89-1.08 
Thigh 0.76 0.67-0.86 0.91 0.76-1.08 
 
OR, Odds ratio; CI, Confidence interval; BMI, Body mass index; UAC, upper arm circumference.  
* Model adjusted for relaxed UAC 
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Table 3. Global Fit and Accuracy of the Different Tools before and after 
calibration 
Screening Tools Hosmer- Lemeshow GOF test (p value) AUC 
OST <0.001 0.73 
OST Calibrated 0.244 0.73 
MORES  0.002 0.75 
MORES Calibrated 0.663 0.75 
EPIPOST 0.631 0.76 
OST, Osteoporosis Screening Tool; MORES, Male Osteoporosis Risk Estimation Score; EPIPOST, 
EpiPorto Osteoporosis Screening Tool; GOF, Goodness of fit test; AUC, area under the curve. 
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Table 4. Likelihood Ratios for Different cut-Offs of Calibrated OST, Calibrated 
MORES and EPIPOST 
  Range Prevalence Low BMD LR AUC 
      n (%) Yes (n (%)) No (n (%))     
OST Calibrated* ≤ -2 8 (5.4) 0 (0.0)  8 (8.2) 0.0 
0.73 
  ]-2, -1]  72 (49.0)  15 (30.6) 57 (58.2) 0.5 
  ]-1, 0] 43 (29.3) 21 (42.9) 22 (22.4) 1.9 
    >0 24 (16.3) 13 (26.5)  11 (11.2) 2.4 
Total   147 (100) 49 (100) 98 (100)     
MORES Calibrated ≤ -2 33 (22.4) 3 (6.1) 30 (30.6) 0.2 
0.75 
  ]-2, -1] 27 (18.4) 3 (6.1) 24 (24.5) 0.3 
  ]-1, 0] 46 (31.3) 19 (38.8) 27 (27.6) 1.4 
    >0 41 (27.9) 24 (49.0) 17 (17.3) 2.8 
Total   147 (100) 49 (100) 98 (100)     
EPIPOST ≤ -2 19 (13.0) 1 (2.0) 18 (18.6) 0.1 
0.76 
  ]-2, -1] 48 (32.9) 9 (18.4) 39 (40.2) 0.5 
  ]-1, 0] 47 (32.2) 18 (36.7) 29 (29.9) 1.2 
  ]0, 1] 22 (15.1) 12 (24.5) 10 (10.3) 2.4 
    >1 10 (6.8) 9 (18.4) 1 (1.0) 18.4 
Total  146 (100) 49 (100) 97 (100)   
BMD, Bone Mineral Denstiry; LR, Likelihood ratio; AUC, area under the receiver operating characteristic 
curve; OST, Osteoporosis Screening Tool; MORES, Male Osteoporosis Risk Estimation Score; 
EPIPOST, EpiPorto Osteoporosis Screening Tool 
 
* To simplify results interpretation, OST results are presented inverted.  
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Figure 1. Calibration of MORES ans OST: prevalence of low bone mineral density before and after 
calibration through quartiles of the different scores. To simplify results interpretation, OST results are 
presented inverted. 
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Appendix 1 
OST = β0 + 0.2 (body weight in Kg−age in years) 
OST = 3.03 + 0.2 (body weight in Kg−age in years) 
OSTcalibrated = β0 + β1 (body weight in Kg−age in years) 
OSTcalibrated = 0.63 + 0.33 (body weight in Kg−age in years) 
MORES = β0 + β1 (Age 56-65 years) + β2 (Weight≤70 Kg) + β3 (80Kg>Weight>70Kg) + 
β4*COPD 
MORES = -3.02 + 1.29 (Age 56-65 years) + 3.07 (Weight≤70 Kg) + 1.86 
(80Kg>Weight>70Kg) + 1.32*COPD 
MOREScalibrated = β0+ β1 (Age 56-65 years) + β2 (Weight≤70 Kg) + β3 
(80Kg>Weight>70Kg) + β4*COPD 
MOREScalibrated = -2.47 + 0.70 (Age 56-65 years) + 2.01 (Weight≤70 Kg) + 2.13 
(80Kg>Weight>70Kg) + 1.32*COPD 
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CONCLUSION 
Our systematic review identified 22 studies validating 9 tools aimed to identify men with 
low BMD benefiting from DXA testing. However, of these, only 3 (OST, OSTA and 
MORES) were validated in more than in one sample. Despite high methodological 
heterogeneity across studies, tools screening for low BMD in men seem to have 
acceptable accuracy but no tool performed consistently better than other. OST and 
MORES, for their simplicity, accuracy and replication, seem to be more adequate for 
routine clinical practice use. 
Calibration of OST and MORES improved the fit of both models to our population data 
while maintaining their discriminatory ability to identify men with low bone mineral 
density. The newly developed tool specifically for men, EPIPOST, proved to have slightly 
better discriminatory ability than OST and MORES while being simpler to execute. The 
likelihood ratios analysis revealed that individuals scoring OST≤2, MORES>-2 and 
EPIPOST>-2 should undergo DXA testing.  
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